Off-the-shelf cell therapy takes on lymphoma
NCT ID NCT07248163
First seen Jan 04, 2026 · Last updated May 12, 2026 · Updated 22 times
Summary
This early study tests a new type of cell therapy called universal CAR-T cells in people with relapsed or treatment-resistant B-cell non-Hodgkin lymphoma. The therapy targets a protein called CD19 on cancer cells. Up to 6 adults will receive the treatment to check safety and how well it works. The goal is to see if this off-the-shelf approach can control the disease.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NON-HODGKIN LYMPHOMA,B CELL are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-••••
Locations
-
Shanghi Tongji Hospital (Tongji Hospital of Tongji University)
RECRUITINGShanghai, 620000, China
Contact Phone: •••-•••-••••
Conditions
Explore the condition pages connected to this study.